

The C-GUARDIANS IDE Trial for the C-Guard MicroNet Stent, and Context from Longer term European Data

> D. Chris Metzger, MD Ballad CVA Heart & Vascular Institute Kingsport, TN, USA


VEITH VEITH







• So, with standard conventional carotid stents, there is some early post-procedure risk of stroke regardless of the access routes or embolic protection type chosen (*TCAR, proximal protection*, etc.)


VEITH VEITH





















C GUARD : Potential Advantages over Other Micro-Mesh Carotid Stents

- ↑ Conformability with "auto-tapering"
- Exact length compared to elongating stents
- Smaller mesh pores, sewn on outside of stent, no coating
- C GUARD has significantly less restenosis and occlusion issues, with good long term durability data
- Easier to size and deliver the stent
- · Larger matrix stent sizing options; no supply issues




Important Note: The C-GUARD stent is an investigational device ONLY in the US





YEAR	STUDY	PUBLICATION HIGHLIGHTS
2015	CARENET	Safety, Efficacy & Neuroprotection over other stents data
	PARADIGM	All comers population; Excellent clinical results
		Large surgical center; Clinical results over conventional stents historical data
	POLISH VASCULAR REGISTRY	
		OCT comparison CGuard vs CEA; Anticipated CGuard superior procedural results than CEA
	PARADIGM EXTEND	
		Use of CGuard as flow diverter in very high-risk patients beyond carotids; Potential new CGuard indications





C-GUARDIANS TRIAL

- FDA US Pivotal IDE Trial
- US and Europe Trial 315 High risk CEA patients, up to 50 sites; FU 3-5 years
- Primary Endpoint: D/S/MI at 30 days and ipsilateral stroke 1 year
- All trial patients approved by screening committee
- Core lab, CEC, DSMB adjudicated
- Sponsor: INSPIRE MD
- PI: Chris Metzger (US); Piotr Musialek (Europe)

VEITH VEITH

C-GUARDIANS US IDE Pivotal Trial Careful Design and Oversight

- Requires NAV6 distal embolic protection or MoMa Proximal embolic protection systems (best in class protection)
- Clinical sites and (limited) operators carefully selected
- All cases must be approved by a screening committee
- Protocol carefully prepared and revised
- · All cases reviewed early after completion
- Trial combines an excellent stent with experienced operators, mandated procedural techniques, and carefully selected cases

VEITHUR VEITHUR VEITHUR

VEITH

C-GUARDIANS IDE Trial Progress...

- First patients enrolled July 21, 2022
- 235 patients enrolled to date (74.5% enrolled)
- DSMB, CEC reviews: No concerns
- · Promising results to date

VEITH

• C-Guard stent now included in CREST 2 Trial



Conclusions

- The C-Guard MicroNet stent is a unique technology with potential additional "neuroprotection" in a conformable stent with provides maximizes lesion coverage and scaffolding
- Long term comparative data from Europe demonstrates excellent results which are durable in high risk lesions, with intra-lesion imaging confirming excellent plaque exclusion, and lowered DW-MRI emboli

rtant Note: The C-GUARD stent is

• The C-GUARDIANS IDE pivotal trial is ongoing and should provide additional rigorous data

<section-header><section-header>

